CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients With Newly Diagnosed and Relapsed/Refractory Cancer Indications

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02649790
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:43.858858+00:00
Published At: 2025-03-19T00:00:00+00:00
Record Updated At: 2025-03-19
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Relapsed/Refractory Multiple Myeloma (RRMM)", "Metastatic Colorectal Cancer (mCRC)", "Metastatic Castration-Resistant Prostate Cancer (mCRPC)", "Higher-Risk Myelodysplastic Syndrome (HR-MDS)", "Acute Myeloid Leukemia (AML)", "Newly Diagnosed Intermediate/High-Risk MDS"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-03-19"
protocolSection.identificationModule.nctId: "NCT02649790"
protocolSection.identificationModule.officialTitle: "A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients With Newly Diagnosed and Relapsed/Refractory Cancer Indications"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.